Search results

All NICE products on renal cancer. Includes any guidance, advice and quality standards.

Result type

Topic page

Evidence-based recommendations on percutaneous cryotherapy for renal tumours. This involves inserting instruments that apply cold temperatures into the tumour to destroy the cancer cells.

Result type

HealthTech guidance

Published

27 July 2011

Evidence-based recommendations on percutaneous radiofrequency ablation of renal cancer. This involves using heat produced through electrodes placed into the tumour to destroy the cancer cells.

Result type

HealthTech guidance

Published

28 July 2010

Evidence-based recommendations on laparoscopic cryotherapy for renal cancer. This involves inserting a surgical instrument (cryoprobe) to apply freezing temperatures to the tumour and destroy the cancer cells.

Result type

HealthTech guidance

Published

24 August 2011

Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.

Result type

HealthTech guidance

Published

23 February 2013

This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.

Result type

NICE guideline

Last updated

2 August 2023

This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

Result type

Clinical guideline

Last updated

2 October 2023

This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.

Result type

NICE guideline

Published

25 February 2015

This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

Result type

Clinical guideline

Last updated

3 June 2015

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

Result type

NICE guideline

Last updated

25 October 2018

This guideline covers safe and effective prescribing of strong opioids for pain relief in adults with advanced and progressive disease. It aims to clarify the clinical pathway for prescribing and help to improve pain management and patient safety. Care during the last 2 to 3 days of life is covered by NICE's guideline on care of dying adults in the last days of life .

Result type

Clinical guideline

Last updated

3 August 2016

and publication of data on the outcomes of percutaneous cryotherapy for renal cancer in the long term is encouraged. Further research...

Result type

Research recommendation

Published

9 June 2015

Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

10 April 2024

Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

30 September 2020

Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

19 October 2022